ScholarIQanswers from OpenAlex
Melanoma and MAPK Pathways
TopicLeading institutions, researchers & key papers
Melanoma and MAPK Pathways is a topic indexed in ScholarIQ from OpenAlex.
What is known about Melanoma and MAPK Pathways?
ScholarIQrecord summary
This cluster of papers focuses on the mammalian MAP kinase signaling pathways, particularly their role in cancer, with a specific emphasis on melanoma. It covers the genetic mutations, targeted therapies, resistance mechanisms, and the impact of MAP kinase pathways on cell proliferation and immune response.
How many works does Melanoma and MAPK Pathways have?
ScholarIQindexed works
Melanoma and MAPK Pathways has 188 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Melanoma and MAPK Pathways?
ScholarIQopenalex
The OpenAlex for Melanoma and MAPK Pathways is on the source record.
What are the most-cited papers on Melanoma and MAPK Pathways?
ScholarIQmost cited works
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert, L. Thomas, Igor Bondarenko, Steven O’Day, Jeffrey S. Weber, Claus Garbe, Célèste Lebbé, Jean‐François Baurain, Alessandro Testori, Jean‐Jacques Grob, Neville Davidson, Jon Richards, Michele Maio, Axel Hauschild, Wilson H. Miller, Pere Gascón, Michal Lotem, Kaan Harmankaya, Ramy Ibrahim, Stephen Francis, Tai‐Tsang Chen, Rachel Humphrey, Axel Hoos, Jedd D. Wolchok
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
Scott M. Wilhelm, Christopher Carter, LiYa Tang, Dean Wilkie, Angela McNabola, Hong Rong, Charles Chen, Xiaomei Zhang, Patrick W. Vincent, Mark McHugh, Yichen Cao, Jaleel Shujath, Susan L. Gawlak, Deepa Eveleigh, Bruce R. Rowley, Li Liu, Lila Adnane, Mark Lynch, Daniel Auclair, I Taylor, Rich Gedrich, Andrei Voznesensky, Bernd Riedl, Leonard Post, Gideon Bollag, Pamela A. Trail
Genomic Classification of Cutaneous Melanoma
Rehan Akbani, Kadir C. Akdemir, Bülent Arman Aksoy, Monique Albert, Adrian Ally, Samirkumar B. Amin, Harindra Arachchi, Arshi Arora, J. Todd Auman, Brenda Ayala, Julien Baboud, Miruna Balasundaram, Saianand Balu, Nandita Barnabas, John Bartlett, Pam Bartlett, Boris C. Bastian, Stephen B. Baylin, Madhusmita Behera, D. K. Belyaev, Christopher C. Benz, Brady Bernard, Rameen Beroukhim, Natalie Bir, Aaron D. Black, Tom Bodenheimer, Lori Boice, Genevieve M. Boland, R. Bono, Moiz Bootwalla, Marcus Bosenberg, Jay Bowen, Reanne Bowlby, Christopher A. Bristow, Laura Brockway-Lunardi, Denise Brooks, Jakub Brzezinski, Wiam Bshara, Elizabeth Buda, William R. Burns, Yaron S.N. Butterfield, M. Button, Tiffany L. Calderone, Giancarlo Antonini Cappellini, Candace Carter, Scott L. Carter, Lynn Cherney, Andrew D. Cherniack, Aaron Chevalier, Lynda Chin, Juok Cho, Raymond J. Cho, Yoon‐La Choi, Andy Chu, Sudha Chudamani, Kristian Cibulskis, Giovanni Ciriello, Amanda Clarke, Stephen W. Coons, Leslie Cope, Daniel Crain, Erin Curley, Ludmila Danilova, Stefania D’Atri, Tanja M. Davidsen, Michael A. Davies, Keith A. Delman, John A. Demchok, Qixia A. Deng, Yonathan Lissanu Deribe, Noreen Dhalla, Rajiv Dhir, Daniel DiCara, М С Диникин, Michael Dubina, J. Stephen Ebrom, Sophie Egea, Greg Eley, Jay Engel, Jennifer Eschbacher, Konstantin Fedosenko, Ina Felau, Timothy R. Fennell, Martin L. Ferguson, Sheila Fisher, Keith T. Flaherty, Scott Frazer, Jessica Frick, Victoria Fulidou, Stacey Gabriel, Jianjiong Gao, Johanna Gardner, Levi A. Garraway, Julie M. Gastier-Foster, Carmelo Gaudioso, Nils Gehlenborg, Giannicola Genovese, Mark Gerken, Jeffrey E. Gershenwald, Gad Getz
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn, Carla Milagre, Steven R. Whittaker, Arnaud Nourry, Ion Niculescu-Duvas, Nathalie Dhomen, Jahan Hussain, Jorge S. Reis‐Filho, Caroline J. Springer, Catrin Pritchard, Richard Marais
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
David Planchard, Egbert F. Smit, Harry J.M. Groen, Julien Mazières, Benjamin Besse, Åslaug Helland, Vanessa Giannone, Anthony M. D’Amelio, Pingkuan Zhang, Bijoyesh Mookerjee, Bruce E. Johnson
Where is Melanoma and MAPK Pathways research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Melanoma and MAPK Pathways is open access?
ScholarIQopen access share
100%OPEN ACCESS